|
 |
||||||||
 |
PRESS RELEASES Biokeys Pharmaceuticals Changes Name to ADVENTRX Pharmaceuticals Company To Trade Under the Bulletin Board Symbol AVRX SAN DIEGO –Biokeys Pharmaceuticals Inc. (OTCBB: BKYS), a biopharmaceutical company specializing in Cancer and HIV/AIDS therapeutics, announced today that effective immediately, the company has changed its name to ADVENTRX Pharmaceuticals Inc. (OTCBB: AVRX). In connection with the name change, the company was issued a new stock symbol. Its common stock will now trade under the symbol AVRX on the Nasdaq Bulletin Board. "We believe our new name better reflects the strength of our technology platforms," said Nicholas Virca, ADVENTRX's CEO. "Since we expect to be able to report on significant progress in our clinical development programs in HIV and Cancer as early as next quarter, we feel that our new identity better reflects the ongoing progress that the company has made in its reorganization and more aggressive plans to gain future product approvals." About ADVENTRX Pharmaceuticals ADVENTRX Pharmaceuticals Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The company focuses its energy in cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. The company's new website will be active next week at www.adventrx.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contact: ADVENTRX Pharmaceuticals Inc. Nicholas Jon Virca, 858/271-9671, Fax 858/271-9678 virca@adventrx.com or CEOCast Inc. for Biokeys Pharmaceuticals Inc. Matthew Henderson, 212/732-4300 mhenderson@ceocast.com |
